Baker J B, Barsh G S, Carney D H, Cunningham D D
Proc Natl Acad Sci U S A. 1978 Apr;75(4):1882-6. doi: 10.1073/pnas.75.4.1882.
Experiments probing the mechanism by which glucocorticoids modulate cell proliferation were carried out on serum-free cell cultures of quiescent human diploid foreskin (HF) cells. Added alone, the synthetic glucocorticoid dexamethasone had no effect on cell number. However, dexamethasone enhanced the mitogenic response of HF cells to epidermal growth factor (EGF) by 50% at all EGF concentrations. The mitogenic action of EGF was maximally promoted by a dexamethasone concentration of 100 ng/ml (0.25 muM). Binding studies with (125)I-labeled EGF ((125)I-EGF) suggested that dexamethasone caused this "permissive" effect by modulating cell surface receptors for EGF. Paralleling their increased responsiveness to EGF growth stimulation, dexamethasone-treated cells exhibited a 50-100% increased ability to bind physiological concentrations of (125)I-EGF. A binding increase was apparent after a 4-hr dexamethasone treatment. The dexamethasone-treated cells maintained an increased ability to bind (125)I-EGF during the prolonged exposure to EGF that was required to stimulate cell division. Moreover, the increase in (125)I-EGF binding exhibited a dexamethasone dose-dependence similar to that for the enhancement of EGF mitogenesis, suggesting a relationship between the dexamethasone effects on binding and growth. An investigation of the binding increase showed that it was specific for glucocorticoids, and required protein synthesis. The enhancement of (125)I-EGF binding diminished with increasing concentrations of (125)I-EGF, indicating that dexamethasone caused a qualitative change in the EGF receptors (possibly a change in receptor affinity or cooperativity). The alteration in (125)I-EGF binding may occur as part of a far-reaching dexamethasone-mediated change in the cell surface, because dexamethasone treatment slightly increased the ability of HF cells to bind (125)I-insulin, and decreased by half their ability to bind (125)I-thrombin.
在静止的人二倍体包皮(HF)细胞的无血清细胞培养物上进行了探究糖皮质激素调节细胞增殖机制的实验。单独添加时,合成糖皮质激素地塞米松对细胞数量没有影响。然而,在所有表皮生长因子(EGF)浓度下,地塞米松使HF细胞对EGF的促有丝分裂反应增强了50%。地塞米松浓度为100 ng/ml(0.25 μM)时,EGF的促有丝分裂作用得到最大促进。用(125)I标记的EGF((125)I-EGF)进行的结合研究表明,地塞米松通过调节EGF的细胞表面受体产生这种“允许”效应。与它们对EGF生长刺激的反应性增加相一致,经地塞米松处理的细胞结合生理浓度(125)I-EGF的能力提高了50 - 100%。地塞米松处理4小时后,结合增加明显。在刺激细胞分裂所需的长时间暴露于EGF期间,经地塞米松处理的细胞保持结合(125)I-EGF的能力增强。此外,(125)I-EGF结合的增加表现出与EGF促有丝分裂增强相似的地塞米松剂量依赖性,表明地塞米松对结合和生长的影响之间存在关联。对结合增加的研究表明,它对糖皮质激素具有特异性,并且需要蛋白质合成。随着(125)I-EGF浓度增加,(125)I-EGF结合的增强减弱,表明地塞米松导致EGF受体发生质的变化(可能是受体亲和力或协同性的变化)。(125)I-EGF结合的改变可能是地塞米松介导的细胞表面广泛变化一部分,因为地塞米松处理使HF细胞结合(125)I-胰岛素的能力略有增加,并使其结合(125)I-凝血酶的能力降低一半。